Additional Information

Description

Semaglutide Compound BPI 1 mg/mL is a compounded formulation intended for subcutaneous injection, typically used in the context of weight management. It is based on the active pharmaceutical ingredient semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist. Like the FDA-approved version, it functions by enhancing glucose-dependent insulin secretion, suppressing glucagon secretion, and slowing gastric emptying.

The safety, efficacy, and quality of compounded semaglutide formulations have not been established through FDA evaluation. Compounded products are not subject to the same rigorous regulatory oversight as approved medications. Clinical outcomes may vary depending on formulation and compounding practices. 

Administration is performed via subcutaneous injection, typically once weekly, as directed by a healthcare provider. Injection sites include the abdomen, thigh, or upper arm, with rotation recommended to reduce the risk of injection-site reactions. Patients should be monitored closely for known adverse effects associated with semaglutide, such as nausea, vomiting, diarrhea, and potential risk of pancreatitis.